BARCELONA, Spain I March 13, 2025 I SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations ...
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
Researchers at Kumamoto University have successfully executed a practical trial of a new genome-editing technique that allows ...
The Fiber Broadband Association (FBA) is proud to announce the first annual OpTIC Path™ Rodeo, an exciting competition ...
A human-specific NOVA1 variant changed mouse vocalizations, potentially providing insights into the evolution of language.
Plants survive cold by adjusting at cellular level. Scientists discovered that the PORCUPINE protein helps plants adapt to ...
As climate conditions become increasingly unpredictable, understanding how plants respond to cold is crucial for securing ...
D-backs manager Torey Lovullo made some interesting comments Thursday night, seemingly opening the door to the possibility ...
Ribopeutic Inc. has divulged nucleic acid splicing modulators (particularly, Huntingtin [HTT; HD] [mutant] and/or transcriptional activator Myb [c-Myb]) reported to be useful for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback